GemmaCert’s Recent Study Unveils Major Variance between Labeled and Actual CBD Potency in Marketable Items

GemmaCert’s Recent Study Unveils Major Variance between Labeled and Actual CBD Potency in Marketable Items

GemmaCert, a medical cannabis testing & analyzing solution has lately unveiled the outcomes of a scientific study, which intends to highlight the variance between labeled and measured CBD potency in marketable CBD items. CBD daily items are now easily accessible and widely used in many states. Considering the upsurge of CBD use, the global CBD market is anticipated to reach US$ 9.69 billion by 2025. 

The study was led by Professor Poulas Konstantinos alongside his group from the University of Patras in Greece, who has collaborated with GemmaCert. The outcomes of this study are expected to be presented in Thessaloniki, Greece in April 2020 at the 20th International Congress of the International Society.

Under the umbrella of this study, numerous legalized CBD products from some of the companies of the Greek market have been examined by employing High Performance Liquid Chromatography and GemmaCert analyzing solution. The results have shown that on average, easily available products’ labels understate CBD levels by 50.8%. Viewing the outcomes of the study, the CEO of GemmaCert, Guy Setton has emphasized the significance of accurate CBD dosage labeling.

From cosmetics to edibles, CBD is now seen in many products. Witnessing the expansion of CBD industry, regulatory administration is anticipated to rise substantially. Companies will likely be exposed to liability concerns if the labeling of their products isn’t accurate.